Progress in research of sodium prasterone sulfate in vaginal atrophy

QIN Jinling; SUN Deyou; DING Minghe; LIU Wei; FAN Yanbo; XIA Jun

doi:10.3969/j.issn.1006-0111.2017.03.004

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Sodium prasterone sulfate (DHEAS) and dehydroepiandrosterone (DHEA) are endogenous steroid compounds, which are synthesized and secreted by adrenal gland. They are the precursors of steroid hormones,including sex hormone. Based on intracrine theory,the majority of postmenopausal women will have vaginal atrophy,which is caused by the absence of endogenous hormones,DHEAS or DHEA. Moderate supplementation of DHEAS can relieve the associated symptoms of vaginal atrophy.Many clinical researches have demonstrated that DHEAS can efficiently alleviate the related symptoms of vaginal atrophy.The concentration of androgen and estrogen in patients with long term use of DHEAS are still in the normal intracrine physiological range. Therefore,DHEAS may become the first drug for the treatment of vaginal atrophy in the future.

Progress in research of sodium prasterone sulfate in vaginal atrophy

Mayinglong Pharmaceutical Group Co.Ltd., Wuhan 430064, China

Received Date: 2016-05-24

Rev Recd Date: 2016-11-04

Key words:

Abstract: Sodium prasterone sulfate (DHEAS) and dehydroepiandrosterone (DHEA) are endogenous steroid compounds, which are synthesized and secreted by adrenal gland. They are the precursors of steroid hormones,including sex hormone. Based on intracrine theory,the majority of postmenopausal women will have vaginal atrophy,which is caused by the absence of endogenous hormones,DHEAS or DHEA. Moderate supplementation of DHEAS can relieve the associated symptoms of vaginal atrophy.Many clinical researches have demonstrated that DHEAS can efficiently alleviate the related symptoms of vaginal atrophy.The concentration of androgen and estrogen in patients with long term use of DHEAS are still in the normal intracrine physiological range. Therefore,DHEAS may become the first drug for the treatment of vaginal atrophy in the future.

HTML

Reference (15)

[1]	"dehydroepiandrosterone,vaginal atrophy" [DB/OL]. Available: https://clinicaltrials.gov/ct2/results?term=vaginal+atrophy&Search=Search.
[2]	牛治欣. 阴道萎缩的诊断及治疗进展[J]. 职业与健康, 2007,23(17):1557-1558.
[3]	刘晓霞. 女性围绝经期健康大讲堂(之十三) 女性更年期泌尿生殖系统疾病治疗组合方案[J]. 首都医药, 2012:51-52.
[4]	van Geelen JM, van de Weifer PH, Amolds HT. Urogenital symptoms and resulting discomfort in non-institutionalixed Dutch women aged 50-75 years[J]. Iht Urogynecol J Pelvic Floor Dysfunct, 2000,11(1):9-14.
[5]	曹江霞,周燕. 不同分娩方式对围绝经期女性盆底功能影响的研究[J]. 中国妇幼保健, 2010,25(16):4504-4506.
[6]	王俊玲.女性更年期泌尿生殖系统症状的激素替代治疗研究[J/OL]. 心理医生,2012(5): 110-111. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_xlys-xbyb201205112.
[7]	王丽鸽,崔丽霞. 普罗雌烯治疗绝经后妇女萎缩性阴道炎的有效性及安全性的临床评估[J]. 中国妇幼保健,2007,22(13):1849-1850.
[8]	Labrie F, Luu-The V, Bélanger A, et al. Is dehydroepiandrosterone a hormone?[J]. J Endocrinol, 2005,187(2):169-196.
[9]	Labrie F, Bé langer A, Luu-The V, et al.DHEA and the intracrine formation of androgens an estrogens in peripheral target tissues: its role during aging[J]. Steroids,1998,63(5-6):322-328.
[10]	Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women[J]. J Clin Endocrinol Metab, 1997,82 (10):3498-3505.
[11]	Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women[J]. J Steroid Biochem Mol Biol, 2008,111(3-5):178-194.
[12]	Ke Y, Labrie F, Gonthier R, et al. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration[J]. J Steroid Biochem Mol Biol, 2015,154:186-196.
[13]	Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy[J]. J Sex Med, 2015,12(12):2401-2412.
[14]	Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause[J]. Menopause, 2016,23(3):243-256.
[15]	Labrie F, Montesino M, Archer DF, et al. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner[J]. Climacteric, 2015,18(6):817-825.

Message Board

Progress in research of sodium prasterone sulfate in vaginal atrophy

doi: 10.3969/j.issn.1006-0111.2017.03.004

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views